A cost comparison of amikacin therapy with bedaquiline, for drug-resistant tuberculosis in the UK

Multidrug-resistant tuberculosis (MDR-TB) is a major public health concern in the UK and globally. Treatment is prolonged, more toxic and less effective compared to that for drug susceptible TB. In 2018 and then consolidated in 2019, the World Health Organisation (WHO) published major revisions to guidelines, prioritising the new drug bedaquiline and down-grading the injectable agents (aminoglycosides and polypeptides) which had played a major part in previous guidelines.1,2 Changes were based on meta-analysis data of efficacy, accumulating trial data supporting bedaquiline and ethical concerns regarding the side effect profile of the injectable agents; most notably irreversible ototoxicity with the aminoglycosides and an association with increased mortality for capreomycin.
Source: Journal of Infection - Category: Infectious Diseases Authors: Source Type: research

Related Links:

Antibiotic-loaded bone cement (ALBC) is used to deliver antimycobacterial agents into the focal lesion of musculoskeletal tuberculosis. Although kanamycin is currently used as an antimycobacterial agent for the treatment of multidrug-resistant tuberculosis, there is no information about its suitability in ALBC.
Source: The Journal of Arthroplasty - Category: Orthopaedics Authors: Source Type: research
Source: International Journal of Tuberculosis and Lung Disease - Category: Respiratory Medicine Authors: Tags: ORIGINAL ARTICLES Source Type: research
Source: International Journal of Tuberculosis and Lung Disease - Category: Respiratory Medicine Authors: Tags: ORIGINAL ARTICLES Source Type: research
Source: International Journal of Tuberculosis and Lung Disease - Category: Respiratory Medicine Authors: Tags: CORRESPONDENCE Source Type: research
The World Health Organization (WHO) recently launched the consolidated guidelines on drug-resistant tuberculosis (DR-TB) treatment [1]. They include a new drug classification to manage rifampicin-resistant (RR) and multidrug-resistant (MDR)-TB, while proposing either a shorter regimen (including injectable drugs) or a longer all-oral one as the recommended treatment options. Efficient diagnostic tools are presently available to diagnose resistance to second-line drugs within a few hours (instead of the weeks previously needed) [2]. Therefore, the challenge for National TB Programmes is now to capture these new recommendati...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Editorials Source Type: research
Resistance against first-line drugs for treating tuberculosis (TB) continues to be a major public health challenge that hampers the World Health Organization (WHO)'s End TB strategy [1]. The End TB strategy aims to reduce TB deaths by 95% and new TB cases by 90% between 2015 and 2035. In 2017, the WHO recorded 558 000 cases (range 483 000–639 000) of TB not treatable with rifampicin, the most effective first-line anti-TB drug. Of these, 82% cases were of multidrug-resistant TB (MDR-TB) [2].
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Editorials Source Type: research
This article summarizes the milestones in the development of pretomanid leading to this first regulatory approval.
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
Abstract Mycobacterium tuberculosis (MTB) can cause the terrible tuberculosis (TB), which is reported as one of the most dreadful epidemic. Although many biochemical molecular drugs have been developed to cope with this disease, the drug resistance-especially the multidrug-resistant (MDR) and extensively drug-resistance (XDR)-poses a huge threat to the treatment. However, traditional biochemical experimental method to tackle TB is time-consuming and costly. Benefited by the appearance of the enormous genomic and proteomic sequence data, TB can be treated via sequence-based biological computational approach-bioinfo...
Source: Medicinal Chemistry - Category: Chemistry Authors: Tags: Med Chem Source Type: research
We aimed to assess the main causes of intensive care unit (ICU) readmissions in lung transplant adults and to identify independent predictors of ICU mortality (primary end-point). This Spanish five-centre prospective cohort study enrolled all lung transplant adults with ICU readmissions after post-transplant ICU discharge between 2012 and 2016. Patients were followed until hospital discharge or death. 153 lung transplant recipients presented 174 ICU readmissions at a median (interquartile range) of 6 (2–25) months post-transplant. Chronic lung allograft dysfunction was reported in 39 (25.5%) recipients, 13 of whom (a...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Interstitial and orphan lung disease, Respiratory infections and tuberculosis Original Articles: Infection and lung transplantation Source Type: research
Source: Patient Preference and Adherence - Category: International Medicine & Public Health Tags: Patient Preference and Adherence Source Type: research
More News: Bedaquiline | Infectious Diseases | International Medicine & Public Health | Medical Ethics | Multidrug Resistance | Toxicology | Tuberculosis | WHO